High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Peter S. Conti, John Hilton, Dean F. Wong, Mian M. Alauddin, Robert F. Dannals, Hayden T. Ravert, Alan A. Wilson, James H. Anderson

Research output: Contribution to journalArticlepeer-review

Abstract

The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

Original languageEnglish (US)
Pages (from-to)1045-1051
Number of pages7
JournalNuclear Medicine and Biology
Volume21
Issue number8
DOIs
StatePublished - Nov 1994

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies'. Together they form a unique fingerprint.

Cite this